NURIX THERAPEUTICS INC

Nurix insiders trade big – the CSO buys at a discount, sells at a premium, signaling confidence in its pipeline and potential upside for investors.

Insider sales by NURIX’s chief scientist show a rule‑based plan, not a warning. Gwenn’s August sell keeps a large stake, underscoring confidence in the company’s pipeline and market performance.

CF‑sale at $24.04 shows CFO Hans van Houte’s disciplined, rule‑based strategy amid Nurix’s strategic shift and AI‑driven growth.

Nurix insiders buy options—Paul Silva’s 31,250 shares at $15.86 shows board confidence amid low prices, hinting at future upside but also potential dilution.

Insightful look at CFO Van Houte Hans’s Rule 10b5‑1 sales at Nurix, showing routine trading amid a drop in share price and its impact on investor confidence.

Insightful analysis of Nurix Therapeutics’ insider trade reveals Christine Ring’s balanced buying and selling, underscoring her confidence in the company’s value and providing investors with a nuanced view of the firm’s short‑term outlook and govern…

Ring Christine’s insider buys at Nurix signal leadership confidence—93k options & 43k RSUs reveal a bullish outlook amid pipeline hopes.

Insider buying fuels optimism for Nurix Therapeutics—CFO and execs invest in the stock amid rising buzz, underscoring confidence in a high‑growth biotech’s undervalued profile.

Nurix CSO’s $0.84 share purchase signals confidence in 2026 milestones; analysts upgrade targets, hinting at potential upside to $30‑$35 per share.

Nurix CFO’s fresh stock purchases signal confidence amid a steep decline—read why insider buying could hint at hidden value and future upside.